We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Generic Test Developed for Early Detection of Cancer

By LabMedica International staff writers
Posted on 07 Nov 2018
Print article
Image: The Pathfinder fully automated cell reader-analyzer system allows for optimized multimodal scanning, cell detection and analysis (Photo courtesy of IMSTAR).
Image: The Pathfinder fully automated cell reader-analyzer system allows for optimized multimodal scanning, cell detection and analysis (Photo courtesy of IMSTAR).
Cancer is one of the leading causes of death worldwide. Early detection of cancer significantly raises the chances for an effective treatment. Cancer identification methods are mainly based on imaging, biopsies and a few nonspecific biomarkers.

There were about 18 million cancer cases diagnosed around the world in 2018. The number of new cancer cases per year is expected to reach more than 23 million by 2030. The most common cancers globally are lung cancer, breast cancer, and colorectal cancer.

Scientists at the University of Bradford (Bradford, UK) and their collaborators adapted the Lymphocyte Genome Sensitivity (LGS) technique, modified by a slightly different method and examined 700 more blood samples from 598 patients with cancer or suspected cancer and 102 healthy individuals. To help increase the sensitivity of the test and detect cancer at the level of each individual, they joined with the IMSTAR team (Paris, France) who analyzed the cells with their fully automated Pathfinder cell reader-analyzer system.

The new test, which is called TumorScan, is a highly sensitive test to detect any cancer at an early stage through the response of the white blood cells to UV treatment. These patient blood samples have also been collected at the stage before confirming diagnosis and treatment. There were four of these individuals with cancer who had received anti-cancer treatment. The results from these patients showed a reverse pattern compared to non-treated cancer patients and followed the pattern seen in healthy individuals.

The authors concluded that their study confirms that the modified method, TumorScan, which combines the adapted Comet assay with different UV treatments, designed and fully automated cell reader-analyzer, the IMSTAR Pathfinder, successfully improves the sensitivity of the original test (LGS test) for the detection of samples at the level of the individual. The study was published on October 12, 2018, in the journal FASEB BioAdvances.

Related Links:
University of Bradford
IMSTAR team

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
FLU/RSV Test
Humasis FLU/RSV Combo
New
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.